Galectin therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Galectin therapeutics Contact Number

Galectin Therapeutics

3 hours ago Galectintherapeutics.com Get All

Galectin Therapeutics looks to help patients with NASH cirrhosis and cancer. Galectin’s lead drug (GR-MD-02, or belapectin) is a galectin-3 inhibitor.

Website: https://galectintherapeutics.com/

Category: Contact NumberShow more

Galectin Therapeutics Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Get All

(678) 620-3186

Company Type For Profit. Contact Email [email protected]galectintherapeutics.com. Phone Number (678) 620-3186. Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins

Founders: Anatole Klyosov, James Czirr

Website: https://www.crunchbase.com/organization/pro-pharmaceuticals

Category: Contact NumberShow more

Galectin Therapeutics Inc. Company Profile Norcross, GA

9 hours ago Dnb.com Get All

(678) 620-3186

Find company research, competitor information, contact details & financial data for Galectin Therapeutics Inc. of Norcross, GA. Get the latest business insights from Dun & Bradstreet.

Employees: 7
Phone: (678) 620-3186
Location: 4960 Peachtree Industrial Blvd Ste 240, Norcross, 30071-1580, GA

Website: https://www.dnb.com/business-directory/company-profiles.galectin_therapeutics_inc.24124432385d488e9311a546c48c4e9b.html

Category: Contact NumberShow more

SEC Filing Galectin Therapeutics Inc.

7 hours ago Investor.galectintherapeutics.com Get All

(678) 620-3186

File Number) (IRS Employer. Identification No.) 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240 . Galectin Therapeutics Submits Seamless Adaptively-Designed Phase . Company Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186. [email protected]eutics.com.

Website: https://investor.galectintherapeutics.com/node/15491/html

Category: Contact NumberShow more

SEC Filing Galectin Therapeutics Inc.

7 hours ago Investor.galectintherapeutics.com Get All

(678) 620-3186

Registrant’s telephone number, including area code: (678) 620-3186. N/A (Former name or former address, if changed since last report) On September 13, 2021, Galectin Therapeutics Inc. (the “Company) posted to its website a presentation which is attached hereto as Exhibit 99.1.

Website: https://investor.galectintherapeutics.com/node/16301/html

Category: Contact NumberShow more

Galectin Therapeutics Company Profile Office Locations

8 hours ago Craft.co Get All

Galectin Therapeutics has 697 Twitter Followers. The number of followers has increased 0.7% month over month and increased 2.6% quarter over quarter

Website: https://craft.co/galectin-therapeutics

Category: Contact NumberShow more

Contact – Galecto, Inc.

8 hours ago Galecto.com Get All

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to …

Website: https://galecto.com/contact/

Category: Contact SupportShow more

Galectin Sciences, LLC

8 hours ago Galectinsciences.com Get All

Galectin Sciences, a Georgia-based LLC, is a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The venture, jointly owned by Norcross, Ga.-based Galectin Therapeutics, and Natick, Mass.-based SBH Sciences, was formed based on the scientific understanding of the role that

Website: http://galectinsciences.com/

Category: Contact NumberShow more

EIN 043562325 Galectin Therapeutics Inc, Norcross, Georgia

5 hours ago Eintaxid.com Get All

Galectin Therapeutics Inc is a corporation in Norcross, Georgia. The employer identification number (EIN) for Galectin Therapeutics Inc is 043562325. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.

Website: https://eintaxid.com/company/043562325-galectin-therapeutics-inc/

Category: Contact NumberShow more

James Czirr Founder and Managing Partner @ 10X Fund LP

5 hours ago Crunchbase.com Get All

James Czirr is a biotech entrepreneur and hedge fund manager from Sandpoint, Idaho. Czirr co-founded (with Rod Martin) and is manager and general partner of 10X Fund, L.P.. In 2000 he co-founded Galectin Therapeutics (formerly Pro-Pharmaceuticals), where he currently serves as Executive Chairman; he also was instrumental in the early-stage.

Website: https://www.crunchbase.com/person/james-czirr

Category: Contact NumberShow more

SEC Filing Galectin Therapeutics Inc.

7 hours ago Investor.galectintherapeutics.com Get All

(678) 620-3186

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Harold H. Shlevin, Ph.D. Chief Executive Officer and President . Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd., Suite 240 . Norcross, Georgia 30071 (678) 620-3186

Website: https://investor.galectintherapeutics.com/node/14976/html

Category: Contact NumberShow more

Galectin Therapeutics Launches NAVIGATEnash.com, a

7 hours ago Investor.galectintherapeutics.com Get All

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosisNORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of NAVIGATEnash.com, its

Website: https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-launches-navigatenashcom-resource-both

Category: Contact NumberShow more

Galectin3 is involved in fibrotic disease and cancer

Just Now Galectintherapeutics.com Get All

Galectin proteins, in particular galectin-3, are known to be markedly increased in a number of important diseases including inflammatory diseases, scarring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the …

Website: https://galectintherapeutics.com/about-galectin-3/

Category: Contact NumberShow more

Galectin Therapeutics Inc. (GALT): Once the correct number

2 hours ago Investorshub.advfn.com Get All

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 9:00:00 AM: Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 9:01:03 AM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/1/2021 9:01:40 AM Galectin Therapeutics Strengthens …

Website: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152259146

Category: Contact NumberShow more

Investor FAQs Galectin Therapeutics Inc.

5 hours ago Investor.galectintherapeutics.com Get All

800-509-5586

If your shares are held in your name, you may contact Continental Stock Transfer and Trust, Galectin Therapeutics’ Transfer Agent, at 1-800-509-5586. If your shares are held in street name (by your broker), contact your broker to update your address.

Website: https://investor.galectintherapeutics.com/investor-faqs

Category: Contact NumberShow more

About Us Galectin Therapeutics

2 hours ago Galectintherapeutics.com Get All

About Us. Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer.

Website: https://galectintherapeutics.com/about-us/

Category: Contact NumberShow more

SEC Filing Galectin Therapeutics Inc.

7 hours ago Investor.galectintherapeutics.com Get All

GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada : 001-31791 : 04-3562325 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (IRS Employer. Identification No.) provision of a contact address, fax number,

Website: https://investor.galectintherapeutics.com/node/15546/html

Category: Contact NumberShow more

Developing new treatments for NASH Galectin Therapeutics

1 hours ago Galectintherapeutics.com Get All

Galectin Therapeutics seeks to broaden the scope of galectin-related disease indications and science. Therefore, we have established a number of academic collaborations with investigators and welcome opportunities to work with additional investigators. Click here to contact us.

Website: https://galectintherapeutics.com/pipeline-overview/

Category: Contact NumberShow more

Galectin Therapeutics Inc. VentureRadar

2 hours ago Ventureradar.com Get All

Blade Therapeutics, Inc. USA Private Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases.

Website: https://www.ventureradar.com/organisation/Galectin%20Therapeutics%20Inc_[dot]_/{CompanyLink}

Category: Contact NumberShow more

NAVIGATE Study – Galectin Therapeutics

5 hours ago Navigatenash.com Get All

Galectin Therapeutics Inc. has developed several overarching principles to guide its conduct of clinical research in light of COVID-19. Number one among these is the safety of patients and study site personnel. Health authorities have provided guidance for the conduct of clinical studies during this pandemic, and we follow this guidance carefully.

Website: https://navigatenash.com/

Category: Contact NumberShow more

Development Programs Galectin Therapeutics

4 hours ago Galectintherapeutics.com Get All

Development Programs NASH Cirrhosis. NASH cirrhosis is the end stage of non-alcoholic steatohepatitis (NASH), where the scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH has replaced healthy liver tissue, preventing the liver from functioning normally and potentially causing liver failure and death.

Website: https://galectintherapeutics.com/development-programs/

Category: Contact NumberShow more

Barbara Fox Greater Boston Professional Profile LinkedIn

9 hours ago Linkedin.com Get All

View Barbara Fox’s professional profile on LinkedIn. LinkedIn is the world’s largest business network, helping professionals like Barbara Fox discover inside connections to recommended job

1. 500+ connections
Location: Greater Boston

Website: https://www.linkedin.com/in/barbarasfox

Category: Contact NumberShow more

Galectin Therapeutics (GALT) Company Profile & Overview

6 hours ago Stockanalysis.com Get All

The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.

Website: https://stockanalysis.com/stocks/galt/company/

Category: Contact NumberShow more

Investor Relations Galectin Therapeutics Inc.

5 hours ago Investor.galectintherapeutics.com Get All

NORCROSS, Ga. , June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number

Website: https://investor.galectintherapeutics.com/press-releases?field_nir_news_date_value%5Bmin%5D=&items_per_page=50&page=1

Category: Contact NumberShow more

Galectin Therapeutics Update on the Impact of COVID19

3 hours ago Finance.yahoo.com Get All

Galectin Therapeutics Inc. has developed several overarching principles to guide its conduct of clinical research in light of COVID-19. Number

Website: https://finance.yahoo.com/news/galectin-therapeutics-impact-covid-19-120403984.html

Category: Contact NumberShow more

Galectin Therapeutics Launches NAVIGATEnash.com, a

3 hours ago Finance.yahoo.com Get All

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosisNORCROSS, Ga

1. Author: Galectin Therapeutics Inc.

Website: https://finance.yahoo.com/news/galectin-therapeutics-launches-navigatenash-com-120000917.html

Category: Contact NumberShow more

Events & Presentations Galectin Therapeutics Inc.

6 hours ago Investor.galectintherapeutics.com Get All

Galectin Therapeutics (Nasdaq:GALT) hosted a corporate update webcast on Thursday, May 21, 2015, immediately following the business portion of the Company’s Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer discussed the company’s pipeline of galectin inhibitor compounds and progress in development of treatments for liver

Website: https://investor.galectintherapeutics.com/events-and-presentations

Category: Contact NumberShow more

Galectin Therapeutics Launches NAVIGATEnash.com, a

2 hours ago Marketscreener.com Get All

NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of NAVIGATEnash.com, its dedicated trial website.The new website intends to educate patients and physicians about liver cirrhosis resulting from non-alcoholic steatohepatitis (NASH) as …

Website: https://www.marketscreener.com/quote/stock/GALECTIN-THERAPEUTICS-INC-10274771/news/Galectin-Therapeutics-Launches-NAVIGATEnash-com-a-Resource-for-Both-Patients-and-Physicians-about-i-32893697/

Category: Contact NumberShow more

Careers Archive Galectin Therapeutics

1 hours ago Galectintherapeutics.com Get All

Careers. While there are no current openings, we are always looking for highly motivated individuals with a relevant background in the life sciences. Please include your contact information and submit your resume/CV and cover letter below.

Website: https://galectintherapeutics.com/careers/

Category: Contact NumberShow more

Artciles from Dr. Peter Traber of Galectin Therapeutics

4 hours ago Perspectives.galectintherapeutics.com Get All

Written by Peter G. Traber, M.D. on September 2, 2015 In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of its anti-galectin drug GR-MD-02 to treat patients with cirrhosis of the liver due to fatty …

Website: http://perspectives.galectintherapeutics.com/articles/

Category: Contact NumberShow more

GALECTIN THERAPEUTICS INC. : Shareholders Board Members

6 hours ago Marketscreener.com Get All

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of …

Website: https://www.marketscreener.com/quote/stock/GALECTIN-THERAPEUTICS-INC-10274771/company/

Category: Contact NumberShow more

Jeff Moore CFO, Flagship Labs Flagship Pioneering

7 hours ago Linkedin.com Get All

Flagship Pioneering. Jun 2019 - Present2 years 3 months. Cambridge, Massachusetts.

Title: CFO, Flagship Labs
Location: Cambridge, Massachusetts, United States
1. 500+ connections

Website: https://www.linkedin.com/in/jeff-moore-0b7a5229

Category: Contact NumberShow more

Galectin Therapeutics Inc. (GALT) Shows Downtrend But

9 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 58.31 million. GALT does have institutional investors; and they hold 13.10% of the stock. Galectin Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 6 new insider purchases involving 31,344 shares.

Website: https://baxterreport.com/2021/09/20/galectin-therapeutics-inc-galt-shows-downtrend-but-still-123-08-up-from-recent-low/

Category: Contact NumberShow more

10X Fund LP Investments, Portfolio & Company Exits

Just Now Crunchbase.com Get All

Their most recent investment was on May 10, 2010, when Galectin Therapeutics raised $570K. 10X Fund LP has had 1 exit, which was Galectin Therapeutics. Investments Number

Website: https://www.crunchbase.com/organization/10x-fund-lp/recent_investments

Category: Contact NumberShow more

Galectin Perspectives Galectin Therapeutics

5 hours ago Perspectives.galectintherapeutics.com Get All

Contact Us; About Galectin Therapeutics (Nasdaq: GALT) Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Search. Search for:

Website: http://perspectives.galectintherapeutics.com/

Category: Contact NumberShow more

Galectin Therapeutics Inc. Common Stock (GALT) Stock Price

Just Now Nasdaq.com Get All

678 620-3186

About Galectin Therapeutics Inc. 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240, NORCROSS, Georgia, 30071, United States +1 678 620-3186. Galectin Therapeutics

Website: https://www.nasdaq.com/market-activity/stocks/galt

Category: Contact NumberShow more

How to buy Galectin Therapeutics stock (NASDAQ: GALT

4 hours ago Finder.com Get All

Galectin Therapeutics share price volatility. Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.91 up to $5.7. A popular way to gauge a stock's volatility is its "beta". GALT.US volatility (beta: 2.35) Avg. volatility (beta: 1.00) Low High.

Website: https://www.finder.com/buy-galectin-therapeutics-stock

Category: Contact NumberShow more

GRMD02 Plus Pembrolizumab in Melanoma, Nonsmall Cell

7 hours ago Clinicaltrials.gov Get All

This study will employ a 3+3 phase I design with dose escalation of GR-MD-02 in conjunction with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma who have had progression after ipilimumab and/or BRAF targeted therapy when a BRAF mutation is present, non-small cell lung cancer patients with disease progression after targeted therapy, or head …

Website: https://clinicaltrials.gov/ct2/show/NCT02575404

Category: Cell PhoneShow more

Galectin Therapeutics : Secures $20 Million Debt Financing

8 hours ago Marketscreener.com Get All

September 22, 2021

Website: https://www.marketscreener.com/quote/stock/GALECTIN-THERAPEUTICS-INC-10274771/news/Galectin-Therapeutics-Secures-20-Million-Debt-Financing-from-Chairman-Richard-Uihlein-36479288/

Category: Contact NumberShow more

The Patent Portfolio Strategy Behind GRMD02 • NASH

1 hours ago Perspectives.galectintherapeutics.com Get All

Galectin Therapeutics holds a process patent that covers the manufacture GR-MD-02 from the pectin (U.S. patent No. 8,962,824). Presumably, a similar process has to be used to manufacture a drug similar to GR-MD-02, and having the process patented adds a second layer of protection to the compound as well.

Website: http://perspectives.galectintherapeutics.com/the-patent-portfolio-strategy-behind-gr-md-02/

Category: Contact NumberShow more

Galectin Therapeutics : Announces $20 Million Convertible

8 hours ago Marketscreener.com Get All

NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt financing agreement with Richard E. Uihlein, the Company’s Chairman and largest individual stockholder.This $20 million convertible debt is in addition …

Website: https://www.marketscreener.com/quote/stock/GALECTIN-THERAPEUTICS-INC-10274771/news/Galectin-Therapeutics-Announces-20-Million-Convertible-Debt-Financing-from-Its-Chairman-Richard-36475704/

Category: Contact NumberShow more

WorldRenowned Neurosurgeon Dr. Ben Carson, Sr. Joins

Just Now Finance.yahoo.com Get All

Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. UihleinNORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc

Website: https://finance.yahoo.com/news/world-renowned-neurosurgeon-dr-ben-120000795.html

Category: Contact NumberShow more

Is Galectin Therapeutics Inc. Common Stock (GALT) a Good

9 hours ago Investorsobserver.com Get All

Galectin Therapeutics Inc. Common Stock is near the top in its industry group according to InvestorsObserver.GALT gets an overall rating of 54. That means it scores higher than 54 percent of stocks. Galectin Therapeutics Inc. Common Stock gets a 82 rank in the Biotechnology industry. Biotechnology is number 86 out of 148 industries.

Website: https://www.investorsobserver.com/news/stock-update/is-galectin-therapeutics-inc-common-stock-galt-a-good-buy-in-the-biotechnology-industry

Category: Contact NumberShow more

Galectin Therapeutics Inc. (GALT): The long term

1 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 58.31 million. GALT does have institutional investors; and they hold 13.10% of the stock. Galectin Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 6 new insider purchases involving 31,595 shares.

Website: https://baxterreport.com/2021/08/26/galectin-therapeutics-inc-galt-the-long-term-indicators-on-the-stock-say-buy-today-2/

Category: Contact NumberShow more

Resources Archive Galectin Therapeutics

3 hours ago Galectintherapeutics.com Get All

Galectin Therapeutics presentation at 2019 Anti-Fibrotic Drug Development (AFDD) Summit. Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics, presented at the 3rd Annual Anti-Fibrotic Drug Development (AFDD) Summit, held from Nov 18 – 20, 2019 in Boston, Massachusetts.

Website: https://galectintherapeutics.com/resources/

Category: Contact NumberShow more

Form 10K SEC

2 hours ago Sec.gov Get All

Galectin proteins, in particular galectin-3, are known to be markedly increased in a number of important diseases including inflammatory diseases, scarring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the …

Website: https://www.sec.gov/Archives/edgar/data/1133416/000119312520073907/d862694d10k.htm

Category: Contact NumberShow more

Galectin Therapeutics Inc. announced that it expects to

7 hours ago Marketscreener.com Get All

alectin Therapeutics Inc. announced that it has entered into a debt financing agreement for a private placement of convertible notes for gross proceeds of $20,000,000 on September 17, 2021.

Website: https://www.marketscreener.com/quote/stock/GALECTIN-THERAPEUTICS-INC-10274771/news/Galectin-Therapeutics-Inc-announced-that-it-expects-to-receive-20-million-in-funding-36486709/

Category: Contact NumberShow more

Galectin Stock Price GALT Macroaxis

7 hours ago Macroaxis.com Get All

Galectin Therapeutic is selling for under 3.74 as of the 14th of September 2021; that is -0.27% down since the beginning of the trading day. The stock's last reported lowest price was 3.68. Get the latest Galectin Therapeutic detailed stock quotes, stock trade data, stock price info, and performance analysis, including Galectin Stock investment advice, charts, stats and more.

Website: https://www.macroaxis.com/stock/GALT/Galectin-Therapeutic

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is galectin therapeutics inc?

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases.

What does galectin therapeutics do for liver disease?

Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.

What kind of drug is galectin for cancer?

Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.

How is galectin 3 related to inflammatory diseases?

Galectin proteins, in particular galectin-3, are known to be markedly increased in a number of important diseases including inflammatory diseases, scarring of organs (e.g. liver, lung, kidney, and heart) and cancers of many kinds. The increase in galectin protein promotes the disease and is detrimental to the patient.

Brand New Updated

Popular Brands

Godrej
Gbl
Geely
Gati
Gic
Gevo
Gaia
Geron
Gpa